Stay updated on Nivolumab for Colon Adenomas in Lynch Syndrome Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Colon Adenomas in Lynch Syndrome Clinical Trial page.

Latest updates to the Nivolumab for Colon Adenomas in Lynch Syndrome Clinical Trial page
- Check3 days agoChange DetectedAdded a site-wide notice about a lapse in government funding, indicating that information on the site may not be up to date and pointing readers to operating status sources. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check10 days agoChange DetectedAdded a 'Show glossary' option on the page. Updated footer/metadata labels to 'Last Update Submitted that Met QC Criteria' (capitalization), added 'No FEAR Act Data', and updated the site revision to v3.4.0 (replacing v3.3.4).SummaryDifference0.2%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedMinor site revision update from v3.3.3 to v3.3.4; page content and study details appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page now shows a Locations section with Ohio as the study site, clarifying where the trial is conducted. The HHS Vulnerability Disclosure link and Ohio Locations label have been removed as minor footer/navigation updates.SummaryDifference0.2%

- Check75 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 was removed.SummaryDifference0.1%

- Check82 days agoChange DetectedRemoved the government funding status notice from the page, a minor change that does not affect trial details, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Nivolumab for Colon Adenomas in Lynch Syndrome Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Colon Adenomas in Lynch Syndrome Clinical Trial page.